A Randomized, Double-Blind, Placebo-Controlled; Phase 1b, Safety, Tolerability, and Pharmacokinetic Study of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled; Phase 1b, Safety, Tolerability, and Pharmacokinetic Study of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs GC 021109 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors GliaCure
  • Most Recent Events

    • 13 Sep 2017 According to an Alzheimers Drug Discovery Foundation media release, data were presented at the 18th Annual Conference on Alzheimer's Drug Discovery.
    • 10 Jun 2017 Biomarkers information updated
    • 14 Dec 2015 According to a GliaCure media release, the company reported pooled clinical results from this and other trial (249753 ) for the treatment of Alzheimer's disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top